Steven Hrycaj, PhD is the technical director of the Immunohistochemistry (IHC) Laboratory and co-director of the Rogel Cancer Center Tissue and Molecular Pathology (TMP) core at the University of ...

When blood cancer cells break through the bone and multiply, tumor cells become dangerously diverse and the immune response ...

From preclinical research to regulatory approval and clinical adoption, diagnostic testing underpins every stage of ADC ...

Lung cancer is a particularly challenging form of cancer. It often strikes unexpectedly and aggressively with little warning, ...

Lunit’s model demonstrated 86.7% accuracy compared to pathologist assessments for HER2 immunohistochemistry ... stop the growth of HER2-positive cancer cells. Lunit CEO Brandon Suh commented ...

This metabolic shift is central to cancer cell aggression and survival ... PDK1 Y163 phosphorylation was further established through immunohistochemical staining of tumor tissue microarrays ...

Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...

Traditionally, immunohistochemistry and in situ hybridization ... Bulk profiles contain transcripts from both cancer and non-cancer cells; the abundance of different cell populations has to ...

During a Case-Based Roundtable event, Laura Huppert, MD, discussed data and considerations around using T-DXd in breast ...

AstraZeneca and Daiichi Sankyo have claimed their seventh FDA approval for Enhertu, getting the go-ahead for the blockbuster ...

Endometrial cancer (EC) ranks as the second most prevalent gynecologic malignancy globally, with approximately 189,000 new ...